[Intentions of systemic glucocorticoid (GC) therapy].
D000284:Administration, Oral; D000328:Adult; D002940:Circadian Rhythm; D003480:Cushing Syndrome / Q000139:chemically induced; D003882:Dermatomyositis / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000150:complications; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use; D007267:Injections / Q000009:adverse effects; D007970:Leukopenia / Q000209:etiology; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D010392:Pemphigus / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012507:Sarcoidosis / Q000188:drug therapy; D012772:Shock, Septic / Q000188:drug therapy; D013440:Sulfides / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology
D005938:Glucocorticoids; D006827:Hydantoins; D013440:Sulfides
Tendenzen der systemischen glucocorticoid-(GC)-Therapie.